In last trading session, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) saw 3.69 million shares changing hands with its beta currently measuring 0.79. Company’s recent per share price level of $15.22 trading at $0.27 or 1.81% at ring of the bell on the day assigns it a market valuation of $2.33B. That closing price of IOVA’s stock is at a discount of -256.18% from its 52-week high price of $54.21 and is indicating a premium of 8.15% from its 52-week low price of $13.98. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.63 million shares which gives us an average trading volume of 1.92 million if we extend that period to 3-months.
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) trade information
Upright in the green during last session for gaining 1.81%, in the last five days IOVA remained trading in the red while hitting it’s week-highest on Friday, 01/07/22 when the stock touched $15.22 price level, adding 10.79% to its value on the day. Iovance Biotherapeutics Inc.’s shares saw a change of -20.27% in year-to-date performance and have moved -5.17% in past 5-day. Iovance Biotherapeutics Inc. (NASDAQ:IOVA) showed a performance of -14.92% in past 30-days. Number of shares sold short was 13.39 million shares which calculate 7.04 days to cover the short interests.
Iovance Biotherapeutics Inc. (IOVA) estimates and forecasts
Statistics highlight that Iovance Biotherapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -32.33% of value to its shares in past 6 months, showing an annual growth rate of -14.36% while that of industry is 7.90. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -19.10% in the current quarter and calculating -15.70% decrease in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -24.70% during past 5 years.
Iovance Biotherapeutics Inc. is more likely to be releasing its next quarterly report between February 23 and February 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Iovance Biotherapeutics Inc. (NASDAQ:IOVA)’s Major holders
Insiders are in possession of 0.60% of company’s total shares while institution are holding 104.42 percent of that, with stock having share float percentage of 105.05%. Investors also watch the number of corporate investors in a company very closely, which is 104.42% institutions for Iovance Biotherapeutics Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at IOVA for having 11.93 million shares of worth $294.17 million. And as of Sep 29, 2021, it was holding 7.60% of the company’s outstanding shares.
The second largest institutional holder is ARK Investment Management, LLC, which was holding about 11.65 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 7.43% of outstanding shares, having a total worth of $287.28 million.
On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF are the top two Mutual Funds which own company’s shares. As of Oct 30, 2021, the former fund manager was holding 5.41 million shares of worth $131.63 million or 3.45% of the total outstanding shares. The later fund manager was in possession of 5.34 million shares on Oct 30, 2021, making its stake of worth around $129.89 million in the company or a holder of 3.41% of company’s stock.